Difference between revisions of "Lung carcinoma with EGFR mutation"
Jump to navigation
Jump to search
| Line 3: | Line 3: | ||
==General== | ==General== | ||
*Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | *Testing indicated in [[non-small cell carcinoma]], [[adenosquamous carcinoma of the lung]], as well as [[lung adenocarcinoma]]. | ||
**Testing done together with ALK. | |||
===Associations=== | ===Associations=== | ||
Revision as of 17:53, 18 June 2017
Lung adenocarcinoma with EGFR rearrangement is a molecular subtype of lung adenocarcinoma.
General
- Testing indicated in non-small cell carcinoma, adenosquamous carcinoma of the lung, as well as lung adenocarcinoma.
- Testing done together with ALK.
Associations
Varies significantly by population:[1]
| Population | Prevalence | Category |
|---|---|---|
| Europe | 14% | Geographic |
| China | 38% | Geographic |
| Females | 44% | Patient characteristics |
| Males | 24% | Patient characteristics |
| Non-smokers | 49% | Patient characteristics |
| Smokers or past smokers | 22% | Patient characteristics |
| Adenocarcinoma | 38% | Pathology |
| Non-adenocarcinoma | 12% | Pathology |
Sign out
Lung core biopsy, left lower lobe: - EGFR mutation POSITIVE, ALK rearrangement NEGATIVE
See also
References
- ↑ Zhang, YL.; Yuan, JQ.; Wang, KF.; Fu, XH.; Han, XR.; Threapleton, D.; Yang, ZY.; Mao, C. et al. (Nov 2016). "The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis.". Oncotarget 7 (48): 78985-78993. doi:10.18632/oncotarget.12587. PMID 27738317.